This work is licensed under a Creative Commons Attribution 4.0 International License.
SEQ ID NO: 17
General Information
DRACP ID DRACP01804
Peptide Name SEQ ID NO: 17
Sequence MXYL
Sequence Length 4
UniProt ID Not available
PubChem CID Not available
Origin Synthetics
Type Synthetic peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| PA-1 | Ovarian mixed germ cell tumor; Mixed germ cell tumor | Germ cell tumor | When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 18.2 ± 1.1, 17.8 ± 1.7, 15.9 ± 0.6, 6.0 ± 0.7 | MTT assay | 48 h | Patent |
| PTC | Papillary thyroid carcinoma | Carcinoma | When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 12.0 ± 1.7, 11.9 ± 1.4, 10.4 ± 0.6, 8.4 ± 1.0 | MTT assay | 48 h | Patent |
| HEp-2 | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 33.6 ± 2.7, 31.7 ± 3.2, 29.0 ± 0.4, 27.9 ± 2.9 | MTT assay | 48 h | Patent |
| Mia PaCa-2 | Pancreatic ductal adenocarcinoma | Carcinoma | When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 23.0 ± 2.1, 21.8 ± 1.9, 17.0 ± 0.9, 16.0 ± 1.4 | MTT assay | 48 h | Patent |
| KB | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 24.9 ± 2.7, 21.9 ± 2.0, 20.5 ± 2.1, 17.9 ± 0.6 | MTT assay | 48 h | Patent |
| ECV-304 | Bladder carcinoma | Carcinoma | When the peptide concentrations were 1 nM, 10 nM, 100 nM, the Percent Cytotoxicity of the tumor was 16.4 ± 1.9, 13.9 ± 0.5, 11.9 ± 1.1, | MTT assay | 48 h | Patent |
| Hep-G2 | Hepatoblastoma; Hepatoblastoma | Blastoma | When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 12.8 ± 0.6, 17.9 ± 1.4, 20.9 ± 1.4, 12.0 ± 0.7 | MTT assay | 48 h | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification X=Saa4=furanoid sugar amino acid
Chiral L
Physicochemical Information
Formula C20H29N3O4S
Absent amino acids ACDEFGHIKNPQRSTVW
Common amino acids LMYX
Mass 57122
Pl 6.09
Basic residues 0
Acidic residues 0
Hydrophobic residues 1
Net charge 0
Boman Index 713
Hydrophobicity 110
Aliphatic Index 97.5
Half Life
/
Extinction Coefficient cystines 1490
Absorbance 280nm 496.67
Polar residues 1
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US7060678B2
Patent Title Peptides comprising furanoid sugar amino acids for the treatment of cancer
Other Iinformation Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 63810703; Filed: Aug 8, 2003; Published: Jun 13, 2006; Earliest Priority: Aug 8, 2003; Granted: Jun 13, 2006
Other Published ID US7060678B2
This work is licensed under a Creative Commons Attribution 4.0 International License.